PHARMAMAR HA OPTADO POR LA RETIRADA DE LA SOLICITUD DE AUTORIZACIÓN DE COMERCIALIZACIÓN DE APLIDIN ( PLITIDEPSIN ) ... WITHDRAWAL OF APPLICATIÓN FOR THE MARKETING AUTHORISATION OF APLIDIN ( PLITIDEPSIN ) JULY 23 , 2025 .
26 abril 2024
ASCO 2024 . IMFINZI ( DURVALUMAB BY ASTRAZÉNECA ) Significantly Improved Overall Survival And Progression-Free Survival For Patients With Limited-Stage Small Cell Lung Cancer In ADRIATIC Phase III Trial .